Insider · CIK 0001734033

Matthews Judith M.

Reports to the SEC for 2 companies · DEERPARK, IL

sec.gov

Transactions

Companies

Filings

CIK

0001734033

Forms 4 and 5

Insider transactions

23 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-07-31	ETONEton Pharmaceuticals, Inc. · Common StockA Award	Chief Financial Officer	AAward	+32.2K sh	—	—	32,246
2023-03-31	ITRMIterum Therapeutics plc · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+100K sh	—	—	100,000
2023-03-11	ITRMIterum Therapeutics plc · Restricted Share UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−6,666 sh	—	—	0
2023-03-11	ITRMIterum Therapeutics plcF Tax Payment	Chief Financial Officer	FTax Payment	−2,883 sh	$0.96	−$2,767.68	8,135
2023-03-11	ITRMIterum Therapeutics plcA Award	Chief Financial Officer	AAward	+6,666 sh	—	—	11,018
2022-03-14	ITRMIterum Therapeutics plcS Sale	Chief Financial Officer	SSale	−63.3K sh	$0.31	−$19.6K	65,292
2022-03-14	ITRMIterum Therapeutics plcS Sale	Chief Financial Officer	SSale	−47.1K sh	$0.38	−$17.9K	81,500
2022-03-11	ITRMIterum Therapeutics plc · Restricted Share UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−100K sh	—	—	100,000
2022-03-11	ITRMIterum Therapeutics plcA Award	Chief Financial Officer	AAward	+100K sh	—	—	128,632
2021-06-23	ITRMIterum Therapeutics plc · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+1.94M sh	—	—	1,936,000
2021-03-11	ITRMIterum Therapeutics plc · Restricted Share UnitsA Award	Chief Financial Officer	AAward	+200K sh	—	—	200,000
2021-01-26	ITRMIterum Therapeutics plcS Sale	Chief Financial Officer	SSale	−33.9K sh	$1.73	−$58.6K	28,632
2021-01-25	ITRMIterum Therapeutics plcA Award	Chief Financial Officer	AAward	+62.5K sh	—	—	62,500
2020-09-30	ITRMIterum Therapeutics plcS Sale	Chief Financial Officer	SSale	−56.1K sh	$1.64	−$92.1K	0
2019-02-15	ITRMIterum Therapeutics plc · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+30K sh	—	—	30,000
2018-05-30	ITRMIterum Therapeutics plc · Series A Preferred SharesC Conversion	Chief Financial Officer	CConversion	−11K sh	—	—	0
2018-05-30	ITRMIterum Therapeutics plc · Series B-2 Preferred SharesC Conversion	Chief Financial Officer	CConversion	−2,466 sh	—	—	0
2018-05-30	ITRMIterum Therapeutics plc · Series B-1 Preferred SharesC Conversion	Chief Financial Officer	CConversion	−3,038 sh	—	—	0
2018-05-30	ITRMIterum Therapeutics plcC Conversion	Chief Financial Officer	CConversion	+11K sh	—	—	46,626
2018-05-30	ITRMIterum Therapeutics plcC Conversion	Chief Financial Officer	CConversion	+3,038 sh	—	—	49,664
2018-05-30	ITRMIterum Therapeutics plcC Conversion	Chief Financial Officer	CConversion	+2,466 sh	—	—	52,130
2018-05-30	ITRMIterum Therapeutics plcP Purchase	Chief Financial Officer	PPurchase	+4,000 sh	$13.00	+$52K	56,130
2018-05-24	ITRMIterum Therapeutics plc · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+23.9K sh	—	—	23,870

Recent filings

Accepted (ET)
Aug 44
Matthews Judith M.0001437749-26-025715
SEC(opens sec.gov)
Apr 34
Matthews Judith M.0001209191-23-022423
SEC(opens sec.gov)
Mar 144
Matthews Judith M.0001209191-23-018585
SEC(opens sec.gov)
Mar 154/A
Matthews Judith M.0001209191-22-018976
SEC(opens sec.gov)
Mar 154
Matthews Judith M.0001209191-22-018864
SEC(opens sec.gov)
Jun 254
Matthews Judith M.0000899243-21-025951
SEC(opens sec.gov)
Mar 154
Matthews Judith M.0000899243-21-011584
SEC(opens sec.gov)
Jan 274
Matthews Judith M.0000899243-21-003518
SEC(opens sec.gov)
Oct 24
Matthews Judith M.0000899243-20-027008
SEC(opens sec.gov)
Feb 194
Matthews Judith M.0000899243-19-003970
SEC(opens sec.gov)
May 304
Matthews Judith M.0001209191-18-034193
SEC(opens sec.gov)

Companies

Address

C/O ETON PHARMACEUTICALS, INC. 21925 W. FIELD PARKWAY, SUITE 235

DEERPARK, IL, 60010-7208